# KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

> clinical trial · VERIFIED · 2026-06-12

Status: RECRUITING · Sponsor: Merck Sharp & Dohme LLC · Condition: Malignant Neoplasm

- Company: Merck Sharp & Dohme LLC
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07252739

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.